Table I:
Baseline Characteristics of the Study Population
| Placebo N = 31 | Adalimumab N = 33 | Phototherapy N = 33 | |
|---|---|---|---|
| Age, in years, mean (SD) | 44.3 (14.5) | 44.2 (14.0) | 42.0 (14.0) |
| Male, N (%) | 20 (60.5) | 24 (72.7) | 23 (69.7) |
| Body Mass Index, mean (SD) | 32.0 (7.7) | 30.9 (7.4) | 32.6 (8.7) |
| Alcohol Mean Standardized Units/week | 2.53 (3.54) | 3.30 (4.50) | 2.59 (3.79) |
| Current Smoker, N (%) | 9 (29.03) | 10 (30.30) | 5 (15.15) |
| Psoriasis duration, in years | 19.3 (13.6) | 15.0 (14.7) | 15.9 (13.6) |
| Psoriatic arthritis, N (%) | 2 (6.5) | 4 (12.1) | 3 (9.1) |
| History of Biologic treatment, N (%) | 11 (35.5) | 10 (30.3) | 8 (24.2) |
| History of Phototherapy, N (%) | 11 (35.5) | 5 (15.2) | 13 (39.4) |
| Psoriasis Assessment, baseline | |||
| BSA, mean (SD) | 25.7 (15.0) | 23.4 (14.5) | 23.0 (13.4) |
| PASI, median (IQR) | 15 (13.3–20.6) | 17.4 (15.4–22) | 16.8 (14.5–21) |
| PGA, mean (SD) | 3.2 (0.6) | 3.4 (0.6) | 3.3 (0.7) |
| Health-related quality of life, baseline | |||
| DLQI, mean (SD) | 12.13 (6.75) | 13.67 (5.90) | 12.79 (7.10) |
| EQ-5D-3L Index, mean (SD) | 0.80 (0.13) | 0.78 (0.14) | 0.72 (0.21) |
| EQ VAS, mean (SD) | 67.58 (23.78) | 53.38 (31.07) | 54.86 (34.55) |